BiotechTube

NUC-3373 + leucovorin + NUC-3373 + NUFOX + NUFOX + VEGF pathway inhibitor + NUFOX + EGFR inhibitor + NUFIRI + NUFIRI + VEGF pathway inhibitor + NUFIRI + EGFR inhibitor + NUC-3373 + bevacizumab

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Colorectal Cancer

Conditions

Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal

Trial Timeline

Oct 5, 2018 → Mar 21, 2024

NCT ID
NCT03428958

About NUC-3373 + leucovorin + NUC-3373 + NUFOX + NUFOX + VEGF pathway inhibitor + NUFOX + EGFR inhibitor + NUFIRI + NUFIRI + VEGF pathway inhibitor + NUFIRI + EGFR inhibitor + NUC-3373 + bevacizumab

NUC-3373 + leucovorin + NUC-3373 + NUFOX + NUFOX + VEGF pathway inhibitor + NUFOX + EGFR inhibitor + NUFIRI + NUFIRI + VEGF pathway inhibitor + NUFIRI + EGFR inhibitor + NUC-3373 + bevacizumab is a phase 1/2 stage product being developed by NuCana for Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03428958. Target conditions include Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma.

What happened to similar drugs?

15 of 20 similar drugs in Colorectal Cancer were approved

Approved (15) Terminated (3) Active (4)
✅Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved
✅Cetuximab (EGFR inhibitor) + Bevacizumab + Irinotecan (CPT-11) + Oxaliplatin + Leucovorin and 5-FU + CapecitabineMerckApproved
✅5-FU based doublet chemotherapy + bevacizumabRocheApproved
✅capecitabine [Xeloda]RocheApproved
✅5-Fluorouracil + Bevacizumab + Irinotecan + OxaliplatinRocheApproved
✅Oxaliplatin + Capecitabine + Bevacizumab + Leucovorin + 5-Fluouracil + IrinotecanRocheApproved
✅CapecitabineRocheApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03428958Phase 1/2Completed

Competing Products

20 competing products in Colorectal Cancer

See all competitors
ProductCompanyStageHype Score
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
35
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
35
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
11
ALIMTA + OxaliplatinEli LillyPhase 2
35
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
25
Bevacizumab + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 1/2
32
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
31
FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOXChugai PharmaceuticalPhase 2/3
38
Gemcitabine and UFTE chemotherapyYuhanPhase 2
35
CPT-11 and TS-1 + CPT-11, 5-FU and l-LVDaiichi SankyoPhase 2/3
38
CPT-11 based regimensDaiichi SankyoPre-clinical
26
CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)Daiichi SankyoPhase 2
35
Tivantinib + Placebo + Cetuximab + IrinotecanDaiichi SankyoPhase 1/2
32
DS-8201a 5.4 mg/kg Q3W + DS-8201a 6.4 mg/kg Q3WDaiichi SankyoPhase 2
35
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
CS-1008 + irinotecanDaiichi SankyoPhase 2
27
CS-7017 + PlaceboDaiichi SankyoPhase 2
27
Patritumab DeruxtecanDaiichi SankyoPhase 2
27
CS-1008 + FOLFIRIDaiichi SankyoPhase 1
29
DS-8273a + nivolumabDaiichi SankyoPhase 1
21